Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT and Mindset App with Esketamine for Treatment-Resistant Depression
NCT05268497Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of esketamine in treatment-resistant depression (TRD), sponsored by Janssen Pharmaceutical. Primary endpoints: System Usability Scale at Week 13, Net Promoter Scale at Week 13 and 3 more. Planned start Sep 2022; status: withdrawn.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05268497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05268497.